Previous Article | Next Article 
Journal of Virology, December 1998, p. 10073-10082, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Distinct Biology of Kaposi's Sarcoma-Associated
Herpesvirus from Primary Lesions and Body Cavity Lymphomas
Jacques
Friborg Jr.,1
Wing-Pui
Kong,1
C. Clay
Flowers,1
Scarlett L.
Flowers,1
Yongnian
Sun,1
Kimberly E.
Foreman,2
Brian J.
Nickoloff,2 and
Gary
J.
Nabel1,*
Departments of Internal Medicine and
Biological Chemistry, Howard Hughes Medical Institute, University
of Michigan Medical Center, Ann Arbor, Michigan
48109-0650,1 and
Skin Disease
Research Laboratories, Department of Pathology, Cardinal Bernardin
Cancer Center, Loyola University Medical Center, Maywood, Illinois
60153-53852
Received 9 March 1998/Accepted 9 September 1998
 |
ABSTRACT |
The DNA sequence for Kaposi's sarcoma-associated herpesvirus was
originally detected in Kaposi's sarcoma biopsy specimens. Since its
discovery, it has been possible to detect virus in cell lines
established from AIDS-associated body cavity-based B-cell lymphoma
and to propagate virus from primary Kaposi's sarcoma lesions in a
human renal embryonic cell line, 293. In this study, we analyzed the
infectivity of Kaposi's sarcoma-associated herpesvirus produced from these two sources. Viral isolates from cultured cutaneous
primary KS cells was transmitted to an Epstein-Barr virus-negative
Burkitt's B-lymphoma cell line, Louckes, and compared to virus induced
from a body cavity-based B-cell lymphoma cell line. While propagation
of body cavity-based B-cell lymphoma-derived virus was not observed in
293 cell cultures, infection with viral isolates obtained from primary
Kaposi's sarcoma lesions induced injury in 293 cells typical of
herpesvirus infection and was associated with apoptotic cell death.
Interestingly, transient overexpression of the Kaposi's
sarcoma-associated herpesvirus v-Bcl-2 homolog delayed the process of
apoptosis and prolonged the survival of infected 293 cells. In
contrast, the broad-spectrum caspase inhibitors Z-VAD-fmk and
Z-DEVD-fmk failed to protect infected cell cultures, suggesting that
Kaposi's sarcoma-associated herpesvirus-induced apoptosis occurs
through a Bcl-2-dependent pathway. Kaposi's sarcoma-associated herpesvirus isolates from primary Kaposi's sarcoma lesions and body
cavity-based lymphomas therefore may differ and are likely to have
distinct contributions to the pathophysiology of Kaposi's sarcoma.
 |
INTRODUCTION |
Kaposi's sarcoma (KS), a recurrent
multifocal angioproliferative disorder, is the most common neoplasm in
patients with AIDS (4, 31). The association of unique viral
DNA sequences in KS lesions was first shown by representational
difference analysis (10). These sequences showed similarity
to several oncogenic herpesviruses, most notably Epstein-Barr
virus (EBV) and herpesvirus saimiri, and the virus was proposed
as a novel member of the gammaherpesvirus family, termed KS-associated
herpesvirus (KSHV) or human herpesvirus 8 (HHV-8). More than 95% of
tumor tissues obtained from patients with AIDS harbor KSHV DNA
sequences. Since then, several investigators have reported the presence
of these sequences in virtually all epidemiologic forms of KS and the
less common AIDS-associated B-cell lymphoproliferative disorders,
such as body cavity-based B lymphomas (BCBL) and multicentric
Castleman's disease (8, 33). In addition, KSHV DNA
sequences have been frequently detected in circulating B cells
and peripheral blood mononuclear cells of AIDS-KS patients (18,
37). These cumulative observations have stimulated extensive
investigations into the properties of this putative new herpesvirus and
its relation to KS pathogenesis.
KS lesions have the features of both hyperplastic proliferation and
neoplastic growth. They often arise synchronously over widely dispersed
areas in immunosuppressed individuals and have been proposed to
originate from the clonal outgrowth of a circulating progenitor cell
(26). Interestingly, seroepidemiological studies indicate a
linear increase in KSHV seropositivity months and even years prior to
the onset of KS (17, 20). Although highly sensitive in situ
techniques or electron microscopic analyses indicate the presence of
KSHV in fresh KS biopsy specimens, viral replication is seldom
prominent (7, 34). Viral DNA sequences appear to be
contained in the nuclei of cells within large circular episomal structures, a genomic form characteristic of latent herpesvirus (13); however, KS spindle-shaped cells, the hallmark of KS
lesions, tend to lose these sequences after in vitro passage. Though
viral production is limited, KS biopsy specimens contain KSHV, and
progeny virions can be propagated serially in the human renal
epithelial cell line 293 (15). Thus, it is not known whether
KSHV DNA sequences found in tumor tissues represent mature virions in a
small fraction of infected cells or cryptic latent infections.
On the other hand, the availability of B-lymphoid cell lines
established from AIDS-associated BCBL has provided fundamental insights
into the molecular biology of KSHV. These cell lines were shown to be
latently infected with KSHV and, in many instances, with EBV strains
that usually infect and transform B lymphocytes (3, 9, 29).
Episomal KSHV DNA copy numbers appear to be 50 to 100 times greater in
BCBL-derived cell lines than in KS biopsy specimens. In addition, upon
induction with phorbol esters (e.g.,
12-O-tetradecanoylphorbol-13-acetate [TPA]), EBV-negative BCBL-derived cell lines can substantially increase virus production (29). Most of the KSHV genome has now been sequenced from
BCBL cell lines and KS specimens (25, 30), and
interestingly, recent reports have suggested that different strains of
KSHV may exist, based on sequence divergence between the two viral DNA
sources (40). In this report, we analyze the transmission of
KSHV in vitro from primary KS specimens to the EBV-negative Burkitt's B-lymphoma cell line Louckes and describe phenotypic differences in
virus from KS lesions grown in B-cell lines compared to those derived
from a chronically infected BCBL.
 |
MATERIALS AND METHODS |
Cell lines.
BCBL-1 is a B-cell line derived from an
EBV-negative body cavity-based lymphoma that is latently infected with
KSHV (NIH AIDS Research and Reference Reagent Program, Rockville, Md.).
Louckes is an EBV-negative Burkitt's B-lymphoma cell line. Namalwa is an EBV-positive Burkitt's B-lymphoma cell line (kindly provided by
Erle Robertson). All cell lines were grown in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 200 mM
L-glutamine, and antibiotics (penicillin [100 U/ml] and
streptomycin [100 µg/ml]). The human embryonic kidney 293 cells
were maintained as previously described (15). Biopsy specimens from
advanced KS skin lesions (tumor nodule) were obtained from human
immunodeficiency virus (HIV)-infected patients (University of Michigan,
Ann Arbor). These lesions were shown to be DNA PCR positive for KSHV
and negative for other known herpesviruses (herpes simplex virus types
1 and 2, EBV, and cytomegalovirus) and HIV.
Cocultivation conditions.
To generate BKS-1 cell lines,
Louckes cells were seeded at a density of 2 × 105
cells per 0.1 ml of RPMI 1640 medium supplemented with 10% FCS, 200 mM
L-glutamine, and antibiotics into 96-well microplates and incubated for 2 h at 37°C. Suspension cells were covered with eight-well Anopore tissue culture inserts of 0.2-µm pore size (Nunc
Inc.), and early-passage primary KS cells found to be KSHV positive
were seeded at a density of 2 × 104 cells per well.
Four days following cocultivation, Louckes cells were transferred to
24-well plates without KS cells and then propagated at low density
(0.5 × 106 cells/ml) into 25-cm2 flasks.
Chemical induction.
Viable cells, seeded at a density of
106 cells per ml of fresh RPMI 1640 medium supplemented
with 10% FCS, 200 mM L-glutamine, and antibiotics, were
cultured in presence or absence of inducing agent for 12 to 96 h.
TPA (Sigma) was added to a final concentration of 20 ng/ml.
DNA extractions and sources of KSHV.
To prepare total
genomic DNA, cells were harvested, washed once in phosphate-buffered
saline (PBS), resuspended in 5 mM Tris-HCl (pH 7.4) containing 0.5%
sodium dodecyl sulfate (SDS), 2 mM EDTA, and 0.5 mg of proteinase K per
ml, and incubated for 2 h at 56°C. DNA was extracted with
phenol-chloroform, precipitated with ethanol, dried, and resuspended in
TE (10 mM Tris-HCL [pH 8], 1 mM EDTA). Nuclear fractions were
prepared by resuspending the cells in 20 mM Tris (pH 7.9)-3 mM
MgCl2-2 mM CaCl2. Samples were incubated for
20 min on ice, and Nonidet P-40 (NP-40) was added to a final concentration of 0.5%. Nuclei were then separated from the cytoplasmic fraction by centrifugation at 1,500 × g for 15 min.
Pellets were incubated for 24 h at 37°C in presence of
proteinase K, and DNA was subsequently extracted with phenol-chloroform
as described above.
To release cell-associated viral particles, cell-free lysates were
prepared by three cycles of freezing and thawing. To isolate extracellular viral particles, culture media from infected cells (106 cells/ml) were subjected to centrifugation at 3,000 rpm for 10 min and filtered through a 0.45-µm-pore-size membrane.
Cleared supernatants were further centrifuged for 2 h at
25,000 × g at 4°C (Beckman SW28 rotor), and pelleted
viral particles were resuspended in Dulbecco's modified Eagle's
medium (DMEM) and snap-frozen. To confirm the presence of encapsidated
KSHV DNA in pelleted materials, nuclease resistance assays were
performed as previously described (15, 29).
PCR amplification and Southern blot analyses.
Genomic DNA
was analyzed by PCR for KSHV sequences as previously described
(10). Total RNA was isolated from 5 × 106
to 10 × 106 infected cells by using TRIzol (GIBCO
BRL), and contaminating genomic DNA was eliminated with RNase-free
DNase I followed by heat-inactivation of the enzyme. Reverse
transcriptase (RT)-mediated PCR (RT-PCR) was performed with 1 µg of
RNA by using the Superscript RT system (GIBCO BRL). Control reactions
were performed with omission of RT. PCR conditions used for the
amplification and/or hybridization of both KSHV DNA and RNA sequences
were as previously described (15). PCR primers and probes for the KSHV
open reading frames (ORFs) were as follow: ORF K7 (T1.1),
5'-GCTTGAGTCAGTTTA GCACTGGGAC-3' (sense) and
5'-GGAGATTGAATCCAATGCAATAACC-3' (antisense); ORF16 (v-Bcl-2), 5'-GCTCAGCCCTATTAAGCTATACATCAC-3' (sense) and
5'-TCATACGCATATACAGGTAAAACGG-3' (antisense); ORF21
(thymidine kinase [TK]), 5'-CGCCTGTGACCGTGGACTACAGGAATGTTT-3' (sense) and 5'-GCGGGTCTCCCGCCTTACCAGACTTCATCA-3'
(antisense); ORF22 (glycoprotein H [gH]),
5'-CCGCCGAAGTCGCCGAGGACCTCAGGGTAA-3' (sense) and
5'-AACAACGAGTCCGGCGTAGCGCTCTATGGA-3' (antisense); ORF25
(major capsid protein [MCP]),
5'-AAGTCATCCAGACAACCCATAATCAAG-3' (sense) and
5'-TTCTCCAGGTGCAGTAGAATATCATCC-3' (antisense); and ORF26
(minor capsid protein [mCP]), 5'-AGCCGAAAGGATTCCACCATTGTGCTC-3' (sense) and 5'-TCCGTGTTGTCTACGTCCAGACGATAT-3'
(antisense). PCR primers for the EBNA-2 gene of EBV type 1 or 2 were as previously described (2). A primer set specific for
the human
-actin cDNA was used as a quantitative control. Southern
blot analysis of genomic DNA was performed with a
32P-labeled 233-bp KSHV-specific probe derived from the MCP
gene as previously described (15).
ISH analysis.
Cells were washed twice with PBS and
resuspended at a density of 106 cells/100 µl of PBS. Cell
suspensions were cytospun onto slides and fixed in 4% paraformaldehyde
(pH 7.4) for 20 min at room temperature. In situ hybridization (ISH)
was performed as previously described (16). A 2.9-kb
(encompassing bp 36,688 to 39,594) and a 9.5-kb (encompassing bp 37,676 to 47,183) PCR fragment cloned from the BCBL-1 cell line were labeled
with digoxigenin-dUTP by nick translation to generate an HHV-8-specific
probe. The hybridized probes were visualized by staining with alkaline
phosphatase-conjugated antidigoxigenin antibodies (Boehringer Mannheim)
according to the manufacturer's instructions.
In situ transmission electron microscopic (TEM)
analysis.
BKS-1 and BCBL-1 cells, untreated or treated with
TPA, were harvested by centrifugation at 200 × g for 5 min. Cell pellets were resuspended in 2.5% glutaraldehyde in PBS (pH
7.4) and incubated for 5 min at room temperature. The cells were then
centrifuged at 200 × g for 5 min and incubated for
2 h at 4°C. The samples were rinsed, dehydrated, and embedded in
Epon. The specimens were sectioned, stained with uranyl acetate and
lead citrate, and examined with a Zeiss 109 transmission electron microscope.
Plasmids and transient transfection assay.
Full-length KSHV
v-Bcl-2 cDNAs from BCBL-1 and BKS-1 cells were amplified by PCR and
subcloned into the mammalian expression vector pCR3.1 (Invitrogen)
according to the manufacturer's instructions. Plasmids containing
v-bcl-2 in the reverse orientation relative to the
cytomegalovirus promoter-enhancer in pCR3.1 were also obtained. In
vitro translation of the different constructs (1 µg) was carried out
with the TNT T7 quick-coupled transcription/translation system (Promega) in the presence of [35S]methionine, and the
reaction mixtures were subjected to SDS-polyacrylamide gel
electrophoresis. For transient expression of v-Bcl-2, 293 cells seeded
at a density of 0.5 × 106 cells per well into
six-well Costar plates were transfected by the calcium phosphate method.
Viral infection.
293 cells were seeded at a density of
106 cells per well into six-well Costar plates and cultured
in DMEM supplemented with 10% FCS, 200 mM L-glutamine, and
antibiotics for 24 h. Culture medium was replaced with 0.8 ml of
fresh DMEM, and cells were inoculated with 0.2 ml of DNase-treated
pelleted viral particles harvested from supernatants of uninduced or
TPA-induced BKS-1 or BCBL-1 cells. Following adsorption for 1 h,
cells were washed once with PBS, and DMEM supplemented with 10% FCS,
200 mM L-glutamine, and antibiotics was added. Cells were
incubated at 37°C in the presence or absence of 100 µM Z-VAD-fmk or
Z-DEVD-fmk (Enzyme System Products, Dublin, Calif.). Cell viability and
growth in the cultures were monitored daily by the trypan blue
exclusion method. Live and dead cells were scored in duplicate by
microscopic examination. To delineate apoptotic and necrotic cell
populations in the infected cultures, aliquots of cells were stained
with fluorescein isothiocyanate (FITC)-conjugated annexin-V (Boehringer Mannheim) and propidium iodide (PI), and preparations were analyzed by
flow cytometry according to the manufacturer's instructions.
 |
RESULTS |
Transmission of KSHV DNA sequence in Louckes cells.
We first
analyzed the transmission of KSHV in vitro from primary KS lesions to
an EBV-negative Burkitt's B-lymphoma cell line, Louckes, which has
proven invaluable in studies of the EBV life cycle (36, 39).
Primary cell lines established from two AIDS-associated cutaneous KS
biopsy specimens were cocultured with Louckes cells separated by
Anopore inserts of 0.2-µm pore size. Four days after cocultivation,
the majority of cocultured Louckes cells showed altered morphology and
reduced cell growth compared to uninfected cells, and the KS spindle
cells, deprived of scatter factor which is required for their growth
(15), were no longer detectable in the cell culture.
PCR analysis of genomic DNA from cocultured Louckes cells revealed the
presence of several KSHV-encoded genes but no EBV DNA
(Fig.
1A and
B). The intensity of the KSHV DNA signal
in these
cells was typically less than that of a single-copy cellular
gene,
encoding

-actin (Fig.
1B, lower panel). The KSHV DNA signal
was
much higher in the chronically infected lymphoma BCBL-1 (Fig.
1A,
upper panel). Indeed, quantitative PCR analysis using the
TaqMan PCR
detection system (Applied Biosystems) indicated ~80
episomal DNA
copies per cell in BCBL-1, compared to <1 copy per
cell in Louckes
cells infected with KSHV (Fig.
1C), herein termed
BKS-1 cells. In these
analyses, an exponential increase in viral
DNA copy number was noted in
BKS-1 cells, which appeared more
prominent upon stimulation with TPA
(Fig.
1C, day 11). It is important
to note that the multiplicity of
infection in Louckes cells was
estimated to be

0.01, which partly
explains the lower initial
copy number per cell and subsequent increase
with time after exposure
to virus (Fig.
1C). These observations were
consistent with previous
reports showing detection of higher genomic
copy numbers in BCBL
cell lines than in primary KS lesions
(
29).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 1.
Transmission of KSHV DNA sequences from primary KS
lesions into Louckes cells. PCR analysis was performed with 1 µg of
total genomic DNA extracted from BCBL-1 and Louckes cells following
cocultivation with primary KS lesions (BKS-1) as described in the text.
PCR products were separated by electrophoresis on an ethidium
bromide-stained agarose gel (2%). Numerous functional and structural
KSHV genes were amplified from both cell lines (A), whereas EBV DNA was
undetectable (B). EBV standard was generated from DNA isolated from
Namalwa cells which contain two integrated EBV genomes per cell, and
cellular -actin was used as a control for PCRs. (C) Quantitative PCR
analysis of KSHV DNA sequences was performed with the TaqMan PCR
detection system (Applied Biosystems) according to the manufacturer's
instructions. Total genomic DNA was extracted from BKS-1 cells
(106) at the indicated times following cocultivation, and
PCR analyses were performed in triplicate, using a custom fluorescent
probe and primers for ORF26 (mCP) of KSHV. At day 9, cells were
cultured in fresh medium containing or lacking TPA (20 ng/ml) for
48 h prior to DNA isolation. (D) Sequence variability of ORF K1
among KSHV DNA samples from different sources. In this summary of the
results of PCR sequencing analysis of two segments of the ORF K1
obtained from a cutaneous KS lesion and BCBL-1, only nucleotides
present at variable positions are given, with positions that differ
from the prototype KSHV sequence (GeneBank accession no. 1102887)
enclosed in black boxes. Primers used and sizes of the PCR products are
as follows: 5'-GTACAATCAAGATGTTCCTGTATG-3' (sense) and
5'-ACAAGTGACTGTGTTTGATGG-3' (antisense), giving a 337-bp product; and
5'-CCGTGTCACAAACTAAATACT-3' (sense) and 5'-TATCTTACCTGAATGTCAGTACCA-3'
(antisense), giving a 478-bp product.
|
|
Sequence divergence at the extreme ends of the KSHV genome was recently
reported for different KSHV isolates (
21,
40).
To determine
whether there were genetic differences between lesion-
and
lymphoma-derived viruses, sequence analysis of ORF K1, located
at the
5' region of the viral genome, was performed. Several nucleotide
changes were noted in DNA from primary KS lesions compared to
the
published BCBL-1-derived KSHV sequence (Fig.
1D). Nucleotide
changes
that resulted in amino acid substitutions included those
at positions
137 (methionine to leucine), 141 (arginine to leucine),
182 (methionine
to leucine), 683 (phenylalanine to serine), 741
(leucine to valine),
778 (threonine to isoleucine), 886 (proline
to asparagine), and 893 (proline to threonine). There was a silent
substitution at base 698 (T
changed to C). These findings documented
that there were genetic
differences between KSHV isolates from
primary KS lesions and B
lymphomas.
KSHV DNA replication in BKS-1 cells.
To assess the levels of
KSHV transmission in the cell cultures, several analyses were
performed. ISH using digoxigenin-labeled DNA probes specific for KSHV
sequence was performed 4 weeks following initial passage. For probe
synthesis in these experiments, a 2.9-kb PCR fragment containing the
lytic gene ORF22 of KSHV (gH) was derived from the BCBL-1 genome, and
equal periods of staining with alkaline phosphate-conjugated
antidigoxigenin were used for all slide preparations. In contrast to
negative controls, KSHV-specific signals were identified in the nucleus
of a small but consistent percentage (1 to 2%) of BKS-1 cells, with
various amounts of cytoplasmic staining (Fig.
2A, panels i and iii). A similar pattern
of staining was observed in latently infected BCBL-1 cells (Fig. 2A,
panel ii). No signal was observed in uninfected Louckes cells (data not
shown). Under identical conditions, we performed ISH analysis of BKS-1
cells treated for 48 h with medium containing or lacking TPA (20 ng/ml). The intensity of KSHV-specific signals increased in BKS-1 cells
after this stimulation, presumably reflecting induction of the
lytic/productive phase of KSHV (Fig. 2A; compare panels iii and iv).
Approximately 20% of the TPA-induced cells were positive for KSHV.
Moreover, significant cytotoxicity was noted in BKS-1 cell cultures by
light microscopy over the ensuing 48 h of treatment with TPA
compared to uninfected Louckes cells exposed to TPA or uninduced BKS-1
cells (data not shown). Finally, to document viral DNA replication in
BKS-1 cells, we performed Southern blot analysis of genomic DNA
isolated at various times following TPA treatment. Viral DNA was
detectable as early as 12 h after TPA stimulation, and signals
increased substantially by 48 h (Fig. 2B, lanes 2 to 4). These
findings suggested transmission and replication of KSHV from KS lesions
to Louckes cells, although the virus did not grow to high titer in this
cell type.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 2.
Viral DNA synthesis in BKS-1 cells. (A) Transmission of
the KSHV genome demonstrated in infected Louckes cells by ISH using
specific KSHV probes. In each experiment, viable cells (106
cell/ml) were washed and cultured in fresh medium containing or lacking
TPA (20 ng/ml) for up to 48 h prior to the preparation of slides
as described in Materials and Methods. (i) No signals were detected in
BKS-1 cells after hybridization with an EBV-specific probe. (ii) In
contrast, nuclei with various amounts of cytoplasmic staining were
identified in the majority of latently infected BCBL-1 cells with a
2.9-kb KSHV-specific probe described in Materials and Methods. (iii)
Under identical conditions of hybridization with the KSHV-specific
probe, a similar pattern of staining was noted in BKS-1 cells. (iv) The
percentage of KSHV-positive BKS-1 cells (~20%) and intensity of
signals increased following treatment with TPA. (B) Southern blot
analysis of genomic DNA (10 µg) isolated from uninduced BKS-1 cells
or at various times after TPA induction. Viral DNA sequences were
detected with a 32P-labeled 233-bp KSHV DNA probe after
digestion with BamHI. The arrow indicates the 330-bp product
expected after digestion with BamHI.
|
|
Induction of lytic replication in BKS-1 cells.
To examine the
pattern of KSHV gene expression in BKS-1 cells, we analyzed viral
transcripts by RT-PCR. Total RNA was extracted from uninduced or
TPA-induced BKS-1 cells 24 h after treatment, and equal amounts of
DNase-treated RNA were subjected to RT-PCR. Both TK and gH KSHV mRNAs
were detected in infected, but not uninfected, Louckes cells (Fig.
3A). These transcripts were more abundant after TPA induction, even though untreated and treated cells showed roughly comparable amounts of cellular
-actin RNA control (Fig. 3B).
No PCR signal was detected without the addition of RT under these
conditions (data not shown), ruling out potential contamination in the
reactions.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 3.
Productive lytic infection in BKS-1 cells. (A)
Expression of KSHV lytic genes encoding TK and gH was examined by
RT-PCR in uninduced or TPA-induced BKS-1 cells. Gene expression was
detected in RNA obtained from uninduced cells (lane 2); levels of
expression in BKS-1 cells increased following TPA induction (lane 3);
no expression of KSHV transcripts was observed in uninfected Louckes
cells (lane 1). (B) RT-PCR for the -actin gene used as a
quantitative control revealed comparable amounts of cDNA amplified from
each sample (lanes 2, 4, and 6). No PCR signal was detected in the
samples without the addition of RT (lanes 1, 3, and 5). (C) Nuclease
sensitivity assay for extracellular enveloped particles derived from
BKS-1 cell cultures. Culture fluids from equivalent amounts of infected
cells were concentrated and incubated with (+) or without ( ) NP-40.
Each preparation was then exposed to pronase and digested with DNase
before nucleic acid extraction. The isolated DNA underwent PCR
amplification, and specific hybridization of PCR products to a
32P-labeled 233-bp KSHV DNA probe was performed as
described in Materials and Methods. Nuclease assay of the BKS-1 cell
culture 1 week (left) and 4 weeks (right) after initial passage.
Cultures fluids of parallel BCBL-1 and BKS-1 cell cultures were
analyzed 48 h after addition of fresh medium containing or lacking
TPA (20 ng/ml).
|
|
To determine whether TPA treatment increased the release of mature KSHV
particles into the media of BKS-1 cells, supernatants
from unstimulated
or TPA-induced BKS-1 cell cultures were ultracentrifuged
and subjected
to nuclease digestion (
15,
29). These fractions
were treated
with pronase and DNase I in the presence or absence
of the nonionic
detergent NP-40, and virus-associated DNA was
analyzed by PCR and
Southern blotting with a radiolabeled KSHV
probe. If the particles were
enveloped, the lipid bilayer would
protect viral DNA sequences from the
combined action of exogenous
protease and nuclease. Indeed, under these
conditions, digestion
of encapsidated KSHV DNA extracted from the
concentrated BKS-1
supernatant fraction was observed only in the
presence of NP-40,
confirming the presence of enveloped mature virions
in the preparation
(Fig.
3C, left). To investigate TPA induction of
KSHV replication
in BKS-1 cells, similar experiments were performed.
For comparison,
supernatants of parallel BCBL-1 and BKS-1 cell cultures
(equivalent
of 5 × 10
6 cells) were harvested 48 h after addition of fresh medium containing
or lacking TPA. PCR and
Southern blotting analyses of the KSHV
genome revealed that viral DNA
replication occurred in both cultures,
and there was a marked increase
in the release of mature particles
after TPA treatment (Fig.
3C,
right).
Finally, the presence of virus particles in TPA-induced BKS-1 cell
cultures was examined by TEM after serial passages. Typically,
condensation and margination of host chromatin were readily apparent
in
the majority of BKS-1 cells (Fig.
4).
These cells also showed
irregular nuclear membranes and edematous
cytoplasm. Although
such changes are consistent with the cell injury
associated with
viral infection, only 1% of the cell nuclei were found
to contain
herpesvirus-like capsids, suggesting possible bystander
killing
or cytotoxicity induced by expression of early viral genes.
These
nucleocapsids contained electron-dense central cores surrounded
by a thick tegument (~100-nm diameter). By contrast, BCBL-1 cells
contained numerous empty capsids in addition to electron-dense
nucleocapsids previously described (
29). We estimate that
~5%
of BCBL-1 which contained viral particles underwent necrosis.
The nuclei of BCBL-1 cells were better preserved than those of
BKS-1
cells, and the cells were nearly completely viable. Mature
enveloped
virions (140 to 160 nm in diameter) were detected in
both cell lines
within cytoplasmic cisternae, in vesicles, and
extracellularly.
Although the electron microscopic observations
alone do not establish
replication competence of virus, these
data, in combination with the
viral DNA replication and transcriptional
analyses, indicate that
Louckes cells are susceptible to KSHV
infection with viral isolates
from primary KS lesions.

View larger version (182K):
[in this window]
[in a new window]
|
FIG. 4.
Visualization of KSHV in BKS-1 by TEM. (A and B) High
(×82,400) magnification of a typical nucleocapsid with an
electron-dense core seen in the nuclei of BKS-1 (A) and BCBL-1 (B)
cells. (C) An enveloped particle morphologically mature in the
extracellular space of a BKS-1 cell (magnification, ×25,900). (D)
General view of a TPA-treated BCBL-1 cell. Numerous empty capsids or
capsids with an electron-dense core (dark arrows) are present within
the nucleus (Nu) of the cell. Electron-opaque bodies showing sites of
assembly of capsids within the nucleus (*) and a cytoplasmic (Cyt)
vesicle containing an enveloped mature particle (arrow) can also be
seen (magnification, ×25,900).
|
|
KSHV from lesions, but not lymphomas, induce apoptosis in 293 cells.
We previously showed that KSHV could be isolated from
cutaneous KS lesions and serially propagated in the human embryonic kidney cell line 293 (15). In this cell system, KS-derived
viruses had the propensity to induce cytotoxicity in infected 293 cell cultures. To determine whether this cytotoxicity was associated with
apoptosis and whether a similar effect was induced by BCBL-1-derived virus, 293 cells were infected with DNase-treated, pelleted viruses from supernatants of TPA-induced BCBL-1 or BKS-1 cells. To detect the
KSHV genome in cell culture, DNA from nuclear fractions was isolated
from uninfected or infected 293 cells at different times after
infection and analyzed by PCR. Although 293 cells were susceptible to
infection with both isolates (Fig. 5A),
lytic growth appeared more prominent with BKS-1-derived virus. Viral
DNA synthesis in infected cells peaked at day 2 in both infected cell
cultures (Fig. 5A, lanes 3 and 8); however, by day 4 viral DNA
sequences were lost in cultures inoculated with virus derived from
BCBL-1, suggesting an abortive infection from the lymphoma-derived
virus (Fig. 5A, lanes 11 to 12). Pretreatment of BKS-1-derived virus by
heat inactivation (65°C for 10 min) or UV irradiation of pelleted viruses prior to adsorption completely eliminated the detection of
viral DNA sequences in 293 cells and its cytotoxic effects (data not
shown).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 5.
KSHV lytic infection induces apoptosis in 293 cells. (A)
Replication of viral DNA in 293 cells infected with viruses derived
from TPA-treated BKS-1 or BCBL-1 cells. Genomic DNA from infected cells
was isolated at the indicated time postinfection and amplified by PCR
using primers for KSHV mCP. PCR products were subjected to
electrophoresis on 2% agarose gels and transfer to nylon membranes.
Hybridization to the same KSHV capsid gene probe revealed bands of 233 bp. (B) Cytotoxicity of KSHV in 293 cells. Cell viability in the
infected cultures was monitored by staining with trypan blue exclusion.
Data shown are the mean of three independent experiments ± standard deviation, and the percentage of cell viability was defined as
the relative number of viable infected cells versus uninfected cells.
(C) Detection of KSHV-induced apoptosis in 293 cells by flow cytometric
analysis. At the indicated time postinfection, aliquots of cells
(106) infected with virus derived from TPA-treated BKS-1 or
BCBL-1 (open curves) were collected and stained with FITC-conjugated
annexin-V and PI. Uninfected cells served as control (solid curve).
Representative histograms of several independent experiments are
shown.
|
|
Concurrent with KSHV DNA synthesis, cell rounding and a loss of
adherence became readily apparent in 293 cell cultures infected
with
BKS-1-derived virus. Cell death in these cultures substantially
increased as early as day 2 after infection (Fig.
5B). By contrast,
no
cytotoxicity was noted in BCBL-1-infected 293 cell cultures,
even
though cell growth was slightly reduced. To determine whether
apoptosis
contributed to KSHV-induced cell death, aliquots of
infected 293 cells
were stained with FITC-conjugated annexin-V
and PI and analyzed by flow
cytometry. Annexin-V binds specifically
to phosphatidylserine, an
integral component of the inner plasma
membrane of healthy cells that
is exposed during the initial steps
of apoptosis. This assay allows
quantitation and delineation of
viable, apoptotic, and necrotic cell
populations. Flow cytometric
analyses showed an increase in annexin-V
immunostaining beginning
1 day after infection (Fig.
5C, upper panel).
After 3 days, 82%
of the cells were either undergoing apoptosis
(annexin-V positive)
or scored as dead cells (PI positive) when
infected with BKS-1-derived
virus, in contrast to the relatively low
levels of cell death
in cultures infected with BCBL-1-derived virus
(Fig.
5C, lower
panel, ~17%).
Expression of KSHV v-Bcl-2 inhibits apoptosis in 293 cells.
The KSHV genome was recently shown to encode a functional v-Bcl-2
homolog (ORF16) expressed both in KS specimens and BCBL cell lines
(11, 32). Therefore, we investigated the functional role of
v-Bcl-2 in regulating apoptosis and prolonging cell survival after
infection by KSHV. Full-length coding sequences of v-Bcl-2 from BCBL-1
and BKS-1 were amplified by PCR and subcloned into the mammalian
expression vector PCR3.1. The proteins were expressed, and bands of
~19.0 kDa were detected on an SDS-polyacrylamide gel (Fig.
6A). 293 cells were then transfected with
increasing amounts of v-Bcl-2 construct and challenged with
BKS-1-derived virus. Within 3 days after infection, v-Bcl-2 increased
cell viability (~50%) in the culture compared to a culture
transfected with the negative control plasmid (~4%). Interestingly,
inclusion of Z-VAD-fmk or Z-DEVD-fmk, both inhibitors of
interleukin-1
-converting enzyme (ICE)-like proteases, had no effect
on cell viability in infected cultures (Fig. 6B). Moreover, the
percentage of annexin-V-staining cells was reduced with increasing
amounts of v-Bcl-2, confirming its ability to protect cells against
apoptosis induced by the virus (Fig. 6C). Similar data were obtained
with both v-Bcl-2 constructs. This effect was not due to an alteration
of viral replication since viral DNA sequences were detected in 293 cells by PCR and Southern blotting analyses (data not shown) with
prolonged incubation, and cytotoxic effects were eventually observed,
suggesting that late gene expression can overcome the protective
effects of v-Bcl-2.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 6.
Transient expression of v-Bcl-2 inhibits KSHV-induced
cytotoxicity in 293 cells. (A) Full-length v-Bcl-2 cDNAs amplified from
BCBL-1 or BKS-1 cells were subcloned into the expression vector pCR3.1.
The proteins were in vitro translated in the presence of
[35S]methionine, separated on an SDS-12% polyacrylamide
gel, and analyzed by autoradiography. No expression was observed with a
construct containing v-bcl-2 in the opposite orientation (antisense).
Positions of molecular weight markers (MW) are indicated in
kilodaltons. (B) 293 cells were transfected with increasing amounts of
plasmids encoding v-Bcl-2 or v-Bcl-2 in the reverse orientation (5 µg) by the calcium phosphate method. At 24 h posttransfection,
the cells were infected with viruses derived from TPA-treated BKS-1
cells. Infected cells were cultured in the presence or absence of 100 µM Z-VAD-fmk or Z-DEVD-fmk. Mock-transfected cell cultures either
uninfected (mock) or inoculated with a viral preparation pretreated by
heat inactivation at 65°C for 10 min (mock-HI) served as controls. At
day 3 postinfection, cell viability in the cultures was monitored by
the trypan blue exclusion method. Data shown are the mean of three
independent experiments ± standard deviation, and the percentage
of viable cells was determined as the relative number of viable cells
versus the total number of cells. (C) In parallel, an aliquot of
infected cells (open curves) was stained with FITC-conjugated annexin-V
and analyzed by flow cytometry. Mock-transfected cells (solid curve)
served as control. Representative histograms of several independent
experiments are shown.
|
|
 |
DISCUSSION |
Limitations in systems which allow productive viral replication
have hampered the characterization of the KSHV life cycle and further
definition of its role in the development of KS lesions. In
AIDS-associated KS lesions, most cells are latently infected and few (1 to 5%) support productive infection (34). Furthermore, KS
spindle cells established in culture tend to lose the viral genome in
early passages (1). In contrast, several lines of evidence
suggest that KSHV replicates more efficiently in other cell types,
including B cells and macrophages (5, 22). Accordingly, KSHV
lytic growth can be induced from the latently infected BCBL cell lines
(3, 29). In addition, the human renal epithelial cell line
293 was shown to be susceptible to viral infection. In recent studies,
serial propagation of KSHV was achieved in 293 cells from KS biopsy
specimens and from saliva of individuals with past or current KS
(15, 35). Herein, we have established transmission
conditions of KSHV from early-passage cell lines derived from cutaneous
KS lesions to an EBV-negative Burkitt's B-lymphoma cell line, Louckes.
Following serial passage, a low level of viral DNA replication and
transcription was detected and further induced by TPA treatment in
presumably latently infected Louckes cells, suggesting that KSHV lytic
growth has occurred in this population (Fig. 1C and 2). Furthermore,
the presence of mature progeny virions was demonstrated by nuclease
sensitivity assays and TEM analysis (Fig. 3 and 4). The Louckes cell
system therefore provides an alternative system for the study of viral gene expression and characterization of the virus life cycle in B-cell lines.
Previous experiments have shown the transmission of KSHV DNA sequences
from BC-1, a cell line that is dually coinfected with EBV, to an
EBV-positive Burkitt's B-lymphoma cell line, Raji; however, the KSHV
genome was lost with serial passages and productive lytic replication
was marginal (24), possibly because the presence of EBV
interfered with KSHV induction or genetic alterations after prolonged
tissue culture occurred in the BC-1 cell line (23, 30). Size
measurements of viral DNA by pulse-field gel electrophoresis analyses
using EBV-positive BCBL-derived cell lines suggested a KSHV genome in
the range of 210 to 270 kb (22, 24). In contrast, the genome
size based on purified encapsidated DNA from BCBL-1 cells was estimated
to be approximately 165 kb, whereas estimates from various KS lesions
indicate a genome larger than 172 kb (28). Reminiscent of
EBV, discrepancies among KSHV DNA sources might be explained by strain
variability or genetic alterations such as rearrangements, mutations,
or deletions. Accordingly, the existence of different KSHV strains has
been suggested, based on DNA sequence heterogeneity between BCBL and KS
specimens (40). In this study, we performed sequencing
analysis of the KSHV ORF K1, located at the extreme 5' end of the
genome, and showed nucleotide divergence between cutaneous KS lesions
and previously reported BCBL viral sequences. Thus, strain variability
exists among different KSHV isolates, particularly those derived from
lesions or lymphomas.
In this regard, we previously reported that KSHV isolates obtained from
primary KS lesions were highly cytopathic upon infection of 293 cells
(15). In the present study, 293 cells exhibited similar
characteristic cytopathic changes associated with infection with
virus-derived from KSHV-positive Louckes cells. Indeed, these cells
were susceptible to apoptosis, as determined by flow cytometry following annexin-V staining (Fig. 4C). Although apoptosis was mediated
by KSHV infection, it appeared to occur in many apparently uninfected
cells, as noted previously (15). Such effects occurred in
293 cells when virus structures were not detected by TEM in morphologically apoptotic cells. Similar findings have been described recently for infection with HHV-6 and HIV type 1 (14, 19). It is possible that viral gene products or cytokines elicited during
infection rendered uninfected bystander cells susceptible to apoptosis.
Nevertheless, entry of virions and transcription of viral DNA was
required for this effect since heat-inactivated viral preparations and
UV-irradiated virions did not induce cell death. In contrast,
virus-derived from TPA-induced BCBL-1 cells did not induce apoptosis in
293 cells. This observation may be the consequence of an abortive
infection since the KSHV genome was lost from these infected cell
cultures and serial passage in 293 cells was ineffective (data not
shown). Alternately, we cannot exclude the possibilities that the two
sources differ in viral gene expression and that genomic divergences
contribute to their respective phenotypes. Renne et al. (27)
recently reported that although 293 cells are highly susceptible to
KSHV infection by virus from induced BCBL-1 cells, replication is not
productive, consistent with the findings of this study. Regardless of
the precise mechanism, viral DNA replication per se correlates with KSHV-induced apoptosis.
Recently, the KSHV genome was shown to encode a functional
v-bcl-2 gene homolog (ORF16) in both KS specimens and BCBL
cell lines (11, 32). Viral replication studies using
recombinant Sindbis viruses harboring KSHV v-Bcl-2 indicated that this
potent cell death suppressor could inhibit Sindbis virus-induced
apoptosis (11). The data reported here document the
antiapoptotic property of v-Bcl-2 in the KSHV life cycle. Transient
transfection experiments using infected 293 cell cultures showed that
expression of this gene product prevented early apoptotic cell death.
In contrast, two broad-spectrum caspase inhibitors, Z-VAD-fmk and
Z-DEVD-fmk, failed to prolong survival in infected cell cultures. These
factors are potent, cell-permeating inhibitors of various forms of
apoptosis, including cell death mediated by Fas/APO-1, dexamethasone,
and HIV (6, 12). Conversely, Z-VAD-fmk does not prevent
nonapoptotic cytolysis (i.e., necrosis) provoked by overexpression of
the cellular death agonist Bak (38). Consistent with this
observation, v-Bcl-2 neither homodimerizes nor heterodimerizes with Bax
and Bak and may have evolved to escape their proapoptotic effects
(11). The terminal effector of KSHV-induced cell death thus
has yet to be defined; however, it is likely a downstream target of
Bcl-2-related proteins. Taken together, these studies strongly suggest
that the KSHV isolates obtained from KS lesions differ biologically from lymphoma-derived viruses, particularly with respect to the cytotoxic effects of the virus from primary lesions. Further
characterization of viruses from these alternative sources will help to
clarify their contributions to the pathogenesis of KS lesions and
AIDS-associated lymphomas.
 |
ACKNOWLEDGMENTS |
We thank Donna Gschwend and Nancy Barrett for manuscript preparation.
This work was supported in part by grant CA46592 from the National
Institutes of Health. J.F. is supported by a fellowship from the
Medical Research Council of Canada.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Howard Hughes
Medical Institute, University of Michigan Medical Center, Departments of Internal Medicine and Biological Chemistry, 1150 W. Medical Center
Dr., 4520 MSRB I, Ann Arbor, MI 48109-0650. Phone: (734) 647-4798. Fax:
(734) 647-4730. E-mail: gnabel{at}umich.edu.
 |
REFERENCES |
| 1.
|
Albini, A.,
M. G. Aluigi,
R. Benelli,
E. Berti,
P. Biberfeld, and C. Blasig.
1996.
Oncogenesis in HIV-infection: KSHV and Kaposi's sarcoma.
Int. J. Oncol.
9:5-8.
|
| 2.
|
Apolloni, A., and T. B. Sculley.
1994.
Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes.
Virology
202:978-981[Medline].
|
| 3.
|
Arvanitakis, L.,
E. A. Mesri,
R. G. Nador,
J. W. Said,
A. S. Asch,
D. M. Knowles, and E. Cesarman.
1996.
Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.
Blood
88:2648-2654[Abstract/Free Full Text].
|
| 4.
|
Beral, V.,
H. Jaffe, and R. Weiss.
1991.
Cancer surveys: cancer, HIV, and AIDS.
Eur. J. Cancer
27:1057-1058.
|
| 5.
|
Blasig, C.,
C. Zietz,
B. Haar,
F. Neipel,
S. Esser,
N. H. Brockmeyer,
E. Tschachler,
S. Colombini,
B. Ensoli, and M. Sturzl.
1997.
Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus 8.
J. Virol.
71:7963-7968[Abstract].
|
| 6.
|
Boise, L. H., and C. B. Thompson.
1997.
Bcl-xL can inhibit apoptosis in cells that have undergone Fas-induced protease activation.
Proc. Natl. Acad. Sci. USA
94:3759-3764[Abstract/Free Full Text].
|
| 7.
|
Boshoff, C.,
T. F. Schulz,
M. M. Kennedy,
A. K. Graham,
C. Fisher,
A. Thomas,
J. O. McGee,
R. A. Weiss, and J. J. O'Leary.
1995.
Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells.
Nat. Med.
1:1274-1278[Medline].
|
| 8.
|
Cesarman, E.,
Y. Chang,
P. S. Moore,
J. W. Said, and D. M. Knowles.
1995.
Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.
N. Engl. J. Med.
332:1186-1191[Abstract/Free Full Text].
|
| 9.
|
Cesarman, E.,
P. S. Moore,
P. H. Rao,
G. Inghirami,
D. M. Knowles, and Y. Chang.
1995.
In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences.
Blood
86:2708-2714[Abstract/Free Full Text].
|
| 10.
|
Chang, Y.,
E. Cesarman,
M. S. Pessin,
F. Lee,
J. Culpepper,
D. M. Knowles, and P. S. Moore.
1994.
Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.
Science
266:1865-1869[Abstract/Free Full Text].
|
| 11.
|
Chen, E. H.,
J. Nicholas,
D. S. Bellows,
G. S. Hayward,
H. Guo,
M. S. Reitz, and J. M. Hardwick.
1997.
A Bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak.
Proc. Natl. Acad. Sci. USA
94:690-694[Abstract/Free Full Text].
|
| 12.
|
Chinnaiyan, A. M.,
C. Woffendin,
V. M. Dixit, and G. J. Nabel.
1997.
The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication.
Nat. Med.
3:333-337[Medline].
|
| 13.
|
Decker, L. L.,
P. Shankar,
G. Khan,
R. B. Freeman,
B. J. Dezube,
J. Lieberman, and D. A. Thorley-Lawson.
1996.
The Kaposi sarcoma-associated herpesvirus (KSHV) is present as an intact latent genome in KS tissue but replicates in the peripheral blood mononuclear cells of KS patients.
J. Exp. Med.
184:283-288[Abstract/Free Full Text].
|
| 14.
|
Finkel, T. H.,
G. Tudor-Williams,
N. K. Banda,
M. F. Cotton,
T. Curiel, and C. Monks.
1995.
Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes.
Nat. Med.
1:129-134[Medline].
|
| 15.
|
Foreman, K. E.,
J. Friborg, Jr.,
W. Kong,
C. Woffendin,
P. J. Polverini,
B. J. Nickoloff, and G. J. Nabel.
1997.
Propagation of a human herpesvirus from AIDS-associated Kaposi's sarcoma.
N. Engl. J. Med.
336:163-171[Abstract/Free Full Text].
|
| 16.
|
Furuta, Y.,
T. Shinohara,
K. Sano,
M. Meguro, and K. Nagashima.
1990.
In situ hybridization with digoxigenin-labelled DNA probes for detection of viral genomes.
J. Clin. Pathol.
43:806-809[Abstract/Free Full Text].
|
| 17.
|
Gao, S.-J.,
L. Kingsley,
M. Li,
W. Zheng,
C. Parravicini,
J. Ziegler,
R. Newton,
C. R. Rinaldo,
A. Saah,
J. Phair,
R. Detels,
Y. Chang, and P. S. Moore.
1996.
KSHV antibodies among Americans, Italians, and Ugandans with and without Kaposi's sarcoma.
Nat. Med.
2:925-928[Medline].
|
| 18.
|
Humphrey, R. W.,
T. R. O'Brien,
F. M. Newcomb,
H. Nishihara,
K. M. Wyvill,
G. A. Ramos,
M. W. Saville,
J. J. Goedert,
S. E. Strauss, and R. Yarchoan.
1996.
Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs.
Blood
88:297-301[Abstract/Free Full Text].
|
| 19.
|
Inoue, Y.,
M. Yasukawa, and S. Fujita.
1997.
Induction of T-cell apoptosis by human herpesvirus 6.
J. Virol.
71:3751-3759[Abstract].
|
| 20.
|
Kedes, D. H.,
E. Operskalski,
M. Busch,
R. Kohn,
J. Flood, and D. Ganem.
1996.
The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission.
Nat. Med.
2:918-924[Medline].
|
| 21.
|
Lagunoff, M., and D. Ganem.
1997.
The structure and coding organization of the genomic termini of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8).
Virology
236:147-154[Medline].
|
| 22.
|
Mesri, E. A.,
E. Cesarman,
L. Arvanitakis,
S. Rafii,
M. A. S. Moore,
D. N. Posnett,
D. M. Knowles, and A. S. Asch.
1996.
Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells.
J. Exp. Med.
183:2385-2390[Abstract/Free Full Text].
|
| 23.
|
Miller, G.,
L. Heston,
E. Grogan,
L. Gradoville,
M. Rigsby, and R. Sun.
1997.
Selective switch between latency and lytic replication of Kaposi's sarcoma herpesvirus and Epstein-Barr virus in dually infected body cavity lymphoma cells.
J. Virol.
71:314-324[Abstract].
|
| 24.
|
Moore, P. S.,
S. J. Gao,
G. Dominguez,
E. Cesarman,
I. Lungu,
D. M. Knowles,
R. Garber,
P. E. Pellett,
D. J. McGeoch, and Y. Chang.
1996.
Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma.
J. Virol.
70:549-558[Abstract].
|
| 25.
|
Neipel, F.,
J.-C. Albrecht, and B. Fleckenstein.
1997.
Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?
J. Virol.
71:4187-4192[Medline].
|
| 26.
|
Rabkin, C. S.,
S. Janz,
A. Lash,
A. E. Coleman,
E. Musaba,
L. Liotta,
R. J. Biggar, and Z. Zhuang.
1997.
Monoclonal origin of multicentric Kaposi's sarcoma lesions.
N. Engl. J. Med.
336:988-993[Abstract/Free Full Text].
|
| 27.
|
Renne, R.,
D. Blackbourn,
D. Whitby,
J. Levy, and D. Ganem.
1998.
Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells.
J. Virol.
72:5182-5188[Abstract/Free Full Text].
|
| 28.
|
Renne, R.,
M. Lagunoff,
W. Zhong, and D. Ganem.
1996.
The size and conformation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions.
J. Virol.
70:8151-8154[Abstract].
|
| 29.
|
Renne, R.,
W. Zhong,
B. Herndier,
M. McGrath,
N. Abbey,
D. Kedes, and D. Ganem.
1996.
Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture.
Nat. Med.
2:342-347[Medline].
|
| 30.
|
Russo, J. J.,
R. A. Bohenzky,
M. C. Chien,
J. Chen,
M. Yan,
D. Maddalena,
J. P. Parry,
D. Peruzzi,
I. S. Edelman,
Y. Chang, and P. S. Moore.
1996.
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).
Proc. Natl. Acad. Sci. USA
93:14862-14867[Abstract/Free Full Text].
|
| 31.
|
Safai, B.,
K. G. Johnson,
P. L. Myskowski,
B. Koziner,
S. Y. Yang,
S. Cunningham-Rundles,
J. H. Godbold, and B. Dupont.
1985.
The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome.
Ann. Intern. Med.
103:744-750.
|
| 32.
|
Sarid, R.,
T. Sato,
R. A. Bohenzky,
J. J. Russo, and Y. Chang.
1997.
Kaposi's sarcoma-associated herpesvirus encodes a functional Bcl-2 homologue.
Nat. Med.
3:293-298[Medline].
|
| 33.
|
Soulier, J.,
L. Grollet,
E. Oksenhendler,
P. Cacoub,
D. Cazals-Hatem, and P. Babinet.
1995.
Kaposi's sarcoma-associated Herpesvirus-like DNA sequences in multicentric Castleman's disease.
Blood
86:1276-1280[Abstract/Free Full Text].
|
| 34.
|
Staskus, K. A.,
W. Zhong,
K. Gebhard,
B. Herndier,
H. Wang,
R. Renne,
J. Beneke,
J. Pudney,
D. J. Anderson,
D. Ganem, and A. T. Haase.
1997.
Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.
J. Virol.
71:715-719[Abstract].
|
| 35.
|
Vieira, J.,
M. Huang,
D. M. Koelle, and L. Corey.
1997.
Transmissible Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in saliva of men with a history of Kaposi's sarcoma.
J. Virol.
71:7083-7087[Abstract].
|
| 36.
|
Wei, M. X.,
J. C. Moulin,
G. Decaussin,
F. Berger, and T. Ooka.
1994.
Expression and tumorigenicity of the Epstein-Barr virus BARF1 gene in human Louckes B-lymphocyte cell line.
Cancer Res.
54:1843-1848[Abstract/Free Full Text].
|
| 37.
|
Whitby, D.,
M. R. Howard,
M. Tenant-Flowers,
N. S. Brink,
A. Copas,
C. Boshoff,
T. Hatzioannou,
F. E. Suggett,
D. M. Aldam,
A. S. Denton,
R. F. Miller,
I. V. Weller,
R. A. Weiss,
R. S. Tedder, and T. F. Schulz.
1995.
Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma.
Lancet
346:799-802[Medline].
|
| 38.
|
Xiang, J.,
D. T. Chao, and S. J. Korsmeyer.
1996.
BAX-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases.
Proc. Natl. Acad. Sci. USA
93:14559-14563[Abstract/Free Full Text].
|
| 39.
|
Zhang, Q.,
L. Brooks,
P. Busson,
F. Wang,
D. Charron, and E. Kieff.
1997.
Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line.
Eur. J. Immunol.
24:1467-1470.
|
| 40.
|
Zong, J.,
C. Metroka,
M. S. Reitz,
J. Nicholas, and G. S. Hayward.
1997.
Strain variability among Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genomes: evidence that a large cohort of United States AIDS patients may have been infected by a single common isolate.
J. Virol.
71:2505-2511[Abstract].
|
Journal of Virology, December 1998, p. 10073-10082, Vol. 72, No. 12
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dourmishev, L. A., Dourmishev, A. L., Palmeri, D., Schwartz, R. A., Lukac, D. M.
(2003). Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis. Microbiol. Mol. Biol. Rev.
67: 175-212
[Abstract]
[Full Text]
-
Lane, B. R., Liu, J., Bock, P. J., Schols, D., Coffey, M. J., Strieter, R. M., Polverini, P. J., Markovitz, D. M.
(2002). Interleukin-8 and Growth-Regulated Oncogene Alpha Mediate Angiogenesis in Kaposi's Sarcoma. J. Virol.
76: 11570-11583
[Abstract]
[Full Text]
-
Dezube, B. J., Zambela, M., Sage, D. R., Wang, J.-F., Fingeroth, J. D.
(2002). Characterization of Kaposi sarcoma-associated herpesvirus/human herpesvirus-8 infection of human vascular endothelial cells: early events. Blood
100: 888-896
[Abstract]
[Full Text]
-
Pertel, P. E.
(2002). Human Herpesvirus 8 Glycoprotein B (gB), gH, and gL Can Mediate Cell Fusion. J. Virol.
76: 4390-4400
[Abstract]
[Full Text]
-
Ma, H. J., Sjak-Shie, N. N., Vescio, R. A., Kaminsky, M., Mikail, A., Pold, M., Parker, K., Beksac, M., Belson, D., Moss, T. J., Wu, C. H., Zhou, J., Zhang, L., Chen, G., Said, J. W., Berenson, J. R.
(2000). Human Herpesvirus 8 Open Reading Frame 26 and Open Reading Frame 65 Sequences from Multiple Myeloma Patients: A Shared Pattern Not Found in Kaposi's Sarcoma or Primary Effusion Lymphoma. Clin. Cancer Res.
6: 4226-4233
[Abstract]
[Full Text]
-
Ojala, P. M., Tiainen, M., Salven, P., Veikkola, T., Castanos-Velez, E., Sarid, R., Biberfeld, P., Makela, T. P.
(1999). Kaposi's Sarcoma-associated Herpesvirus-encoded v-Cyclin Triggers Apoptosis in Cells with High Levels of Cyclin-dependent Kinase 6. Cancer Res.
59: 4984-4989
[Abstract]
[Full Text]
-
(1999). Rebuttal to Tarte, Chang, and Klein. Blood
93: 3163-3164
[Full Text]